亚盛医药－Ｂ(06855.HK)IAP拮抗剂临床研究显示呈现功能性治癒慢性乙肝潜力

AAFN2022-11-07

亚盛医药－Ｂ公布，在第73届美国肝病研究学会年会(AASLD 2022)上以口头报告形式公布其在研凋亡蛋白抑制因子(IAP)拮抗剂APG-1387针对中国慢性乙型肝炎(CHB)患者的I期临床试验的研究结果。该项临床数据显示，APG-1387在12 mg和30 mg剂量下呈现明显的抗乙型肝炎病毒(HBV)活性，且与核苷(酸)类似物(NA)序贯治疗具有积极的协同作用。而APG-1387治疗慢...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2281162184?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2022-11-07 09:17","share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","id":"2281162184","market":"us","top_or_hot":-1,"title":"亚盛医药－Ｂ(06855.HK)IAP拮抗剂临床研究显示呈现功能性治癒慢性乙肝潜力","media":"AAFN","content":"<div>\n<p>亚盛医药－Ｂ  公布，在第73届美国肝病研究学会年会(AASLD 2022)上以口头报告形式公布其在研凋亡蛋白抑制因子(IAP)拮抗剂APG-1387针对中国慢性乙型肝炎(CHB)患者的I期临床试验的研究结果。该项临床数据显示，APG-1387在12 mg和30 mg剂量下呈现明显的抗乙型肝炎病毒(HBV)活性，且与核苷(酸)类似物(NA)序贯治疗具有积极的协同作用。而APG-1387治疗慢...</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1224497&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">网页链接</a>\n\n</div>\n","source":"aastocks","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>亚盛医药－Ｂ(06855.HK)IAP拮抗剂临床研究显示呈现功能性治癒慢性乙肝潜力</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n亚盛医药－Ｂ(06855.HK)IAP拮抗剂临床研究显示呈现功能性治癒慢性乙肝潜力\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-11-07 09:17 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1224497&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0><strong>AAFN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>亚盛医药－Ｂ  公布，在第73届美国肝病研究学会年会(AASLD 2022)上以口头报告形式公布其在研凋亡蛋白抑制因子(IAP)拮抗剂APG-1387针对中国慢性乙型肝炎(CHB)患者的I期临床试验的研究结果。该项临床数据显示，APG-1387在12 mg和30 mg剂量下呈现明显的抗乙型肝炎病毒(HBV)活性，且与核苷(酸)类似物(NA)序贯治疗具有积极的协同作用。而APG-1387治疗慢...</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1224497&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4141","symbol_name":"半导体产品","start_time":0,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1224497&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","article_id":"2281162184","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2281162184","pubTimestamp":1667783832,"sourceInfo":{"source_id":"aastocks","name":"阿思达克财经"},"weMediaInfo":null,"summary":"亚盛医药－Ｂ  公布，在第73届美国肝病研究学会年会上以口头报告形式公布其在研凋亡蛋白抑制因子拮抗剂APG-1387针对中国慢性乙型肝炎患者的I期临床试验的研究结果。该项临床数据显示，APG-1387在12 mg和30 mg剂量下呈现明显的抗乙型肝炎病毒活性，且与核苷(酸)类似物序贯治疗具有积极的协同作用。而APG-1387治疗慢乙肝患者整体是安全且可耐受，呈现功能性治癒慢性乙肝潜力。此外，公司目前一项APG-1387联合恩替卡韦的II期临床研究正在进行。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4141":"半导体产品","NA":"毫微科技","BK1161":"生物科技","06855":"亚盛医药-B","BK1574":"生物医药B类股","CHB":"Global X China Biotech Innovation ETF"},"translate_title":"Clinical study of Yasheng Medicine-B (06855. HK) IAP antagonist shows functional potential for curing chronic hepatitis B","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CHB":1,"NA":1,"06855":0.9},"content_text":"亚盛医药－Ｂ  公布，在第73届美国肝病研究学会年会(AASLD 2022)上以口头报告形式公布其在研凋亡蛋白抑制因子(IAP)拮抗剂APG-1387针对中国慢性乙型肝炎(CHB)患者的I期临床试验的研究结果。该项临床数据显示，APG-1387在12 mg和30 mg剂量下呈现明显的抗乙型肝炎病毒(HBV)活性，且与核苷(酸)类似物(NA)序贯治疗具有积极的协同作用。而APG-1387治疗慢乙肝患者整体是安全且可耐受，呈现功能性治癒慢性乙肝潜力。此外，公司目前一项APG-1387联合恩替卡韦的II期临床研究(NCT04568265)正在进行。(jl/s)~阿思达克财经新闻网址: www.aastocks.com","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2281162184"}